The implications of long non-coding RNA (LncRNA) involvement in lymphomas is not well known. While differential gene expression analysis has been conducted for different stages and classes of diffuse large B cell lymphoma (DLBCL) no study has so far investigated the involvement of the diverse class of LncRNA molecules in disease progression nor the implications of their expression in terms of the aggressiveness of the disease. The ambition of this project is to study global expression of LncRNAs and mRNA in patient DLBCL material stratified on disease aggressiveness. For this purpose we aim to use next generation sequencing of total RNA followed by alignment to the human reference genome, extracting read counts per feature and differential RNA expression between the different DLBCL classes, in total 100 samples. Hopefully this will shed light on the involvement of this somewhat under-studied class of RNA molecules in non-Hodgkin’s lymphoma progression and clinical manifestation and the study might introduce new targets or identify biomarkers affiliated with different clinical disease outcomes. This will be the first study to do so at the global RNA expression level and to do so in a systematic fashion. Given the size of the dataset, slightly too large for what can be handled by our local workstations but still small enough to fit within a small Uppmax project it would be incredibly valuable for us if we would be given access to the Uppmax cluster during the course of the project.